Parvesh Kumar, (Medicine) presented his research findings at the 2016 annual meeting of the American Society of Radiation Oncology (ASTRO) in Boston. The research co-authored by Dr. Kumar highlights Phase 1 -2 cancer trials to determine if a three-pronged treatment for patients undergoing radical prostatectomy (the removal of the prostate gland and surrounding tissue) for certain types of high-risk prostate cancer was safe, tolerable, and effective. The trial results showed the trimodal approach, which comprises radiation therapy, concurrent drug therapy (docetaxel), and hormone therapy, is safe, well tolerated and has a high feasibility rate for these types of patients.

He also presented at the 54th annual meeting of the Japan Society of Clinical Oncology in Yokohama, Japan. He discussed how the treatment of locally advanced head and neck cancer is moving toward precision-targeted medicine, which is personalized for each individual patient. He was one of only three U.S. radiation oncologists invited to present at the conference. The other two researchers were from Harvard Medical School.